ClinicalTrials.gg
WithdrawnNCT04699968Updated Jun 7, 2023

A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC

A Phase 2 interventional study of SHR-1701,Famitinib and SHR-1701 in Non-Small-Cell Lung Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Withdrawn. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-06-07.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Sponsor R \& D Strategy Adjustment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies in Carcinoma, Non-Small-Cell Lung by Jiangsu HengRui Medicine Co., Ltd. — 18 open to participants now, 22 under way, 10 of them phase 3. Carcinoma, Non-Small-Cell Lung · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
37th of 38
0 · median 274
Started
2021
with 4 others
Phase 2
14 of 38
5 open now
Registered
14th of 38
by date

Among the 38 studies in Carcinoma, Non-Small-Cell Lung by Jiangsu HengRui Medicine Co., Ltd., this one is the 37th largest by enrollment, is one of 5 that started in 2021, is one of 14 in phase 2, and was the 14th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

18 of the 38 studies in Carcinoma, Non-Small-Cell Lung by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

Where they have run

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Carcinoma, Non-Small-Cell Lung by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

The study is being conducted to evaluate the efficacy and safety of SHR-1701 with or without famitinib in patients with advanced or metastatic NSCLC

03

Conditions studied

  • Non-Small-Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. voluntarily participate in the study and sign the form;
  2. 18 to 75 years old, both male and female;
  3. or cytologically confirmed stage IIIB-IV or recurrent NSCLC
  4. one prior platinum-containing chemotherapy for advanced or disease;
  5. by v1.1;
  6. score: 0-1;
  7. ≥ 3 months;
  8. adequate hematological, hepatic and renal function;
  9. non-surgically sterile female subjects of childbearing age must have a negative serum HCG test.

Exclusion criteria

Exclusion Criteria:

  1. or cytologically confirmed mixed SCLC and NSCLC;
  2. known sensitising EGFR mutation and/or ALK translocation in patients with non-squamous NSCLC;
  3. tumor infiltration into the great vessels on imaging;
  4. active ;
  5. other than NSCLC within 5 years;
  6. anticancer therapy within 4 weeks before the start of trial treatment;
  7. persisting toxicity related to prior therapy of Grade > 1;
  8. treatment with systemic immunostimulatory agents within 4 weeks;
  9. treatment with systemic agents within 2 weeks;
  10. diseases;
  11. interstitial lung disease or other lung diseases that is symptomatic or may interfere the management of suspected drug-related pulmonary toxicity;
  12. cardiovascular or cerebrovascular diseases;
  13. inadequately controlled hypertension;
  14. history of hemoptysis (≥ 2.5mL of bright red blood per episode) within 1 month;
  15. venous or arterial thrombosis within 6 months;
  16. evidence of bleeding diathesis or coagulopathy;
  17. use of anticoagulants or thrombolytic agents that has not been stable;
  18. active Tuberculosis infection;
  19. significant acute or chronic infections within 1 month;
  20. known history of testing positive test for or known AIDS;
  21. virus or virus infection;
  22. allergic to any component of the treatment regimen;
  23. other conditions that in the opinion of the investigator would make participation in this clinical trial inappropriate.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Treatment group A

    Drug: SHR-1701,Famitinib

  • Experimental
    Treatment group B

    Drug: SHR-1701

Interventions

  • DrugSHR-1701,Famitinib

    SHR -1701, Intravenous ;Famitinib, oral

  • SHR -1701, Intravenous

06

What researchers measure

Primary outcomes

  1. ORR

    Objective Response Rate

    Time frame: determined by RECIST v1.1, up to approximately 1 year

Secondary outcomes

  1. PFS

    Progression-Free-Survival

    Time frame: determined by RECIST v1.1, up to approximately 1 year

  2. DCR

    Disease Control Rate

    Time frame: determined by RECIST v1.1, up to approximately 1 year

  3. DoR

    Duration of Response

    Time frame: determined by RECIST v1.1, up to approximately 1 year

  4. OS

    Overall Survival

    Time frame: up to approximately 1 year

  5. AEs+ SAEs

    Adverse Events and Serious Adverse Events

    Time frame: determined by NCI-CTCAE V5.0, from the first drug administration to within 90 days for the last SHR-1701 dose

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2021; primary completion for Nov 2021, 10 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2021
First posted
Jan 7, 2021
StartEst.
Jan 15, 2021
Primary completionEst.
Nov 15, 2021
CompletionEst.
Nov 15, 2021
Last update
Jun 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04699968
Responsible party
Sponsor
First posted
Jan 7, 2021
Start date
Jan 15, 2021 (estimated)
Primary completion
Nov 15, 2021 (estimated)
Completion
Nov 15, 2021 (estimated)
Last update
Jun 7, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR-1701

Start the discussion